News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
55,504 Results
Type
Article (4981)
Company Profile (13)
Press Release (50510)
Section
Business (17212)
Career Advice (257)
Deals (2674)
Drug Delivery (9)
Drug Development (3077)
Employer Resources (23)
FDA (1136)
Job Trends (1718)
News (24447)
Policy (2205)
Tag
Academia (563)
Allergies (3)
Alliances (5785)
ALS (1)
Alzheimer's disease (119)
Antibody-drug conjugate (ADC) (9)
Approvals (1132)
Artificial intelligence (54)
Autoimmune disease (4)
Automation (8)
Bankruptcy (24)
Best Places to Work (1216)
BIOSECURE Act (1)
Biosimilars (8)
Biotechnology (5)
Bladder cancer (2)
Brain cancer (4)
Breast cancer (17)
Cancer (170)
Cardiovascular disease (12)
Career advice (225)
Career pathing (11)
CAR-T (7)
Cell therapy (30)
Cervical cancer (6)
Clinical research (1965)
Collaboration (102)
Compensation (7)
COVID-19 (516)
CRISPR (8)
C-suite (19)
Cystic fibrosis (7)
Data (121)
Depression (2)
Diabetes (8)
Diagnostics (1736)
Digital health (2)
Diversity, equity & inclusion (3)
Drug discovery (18)
Drug pricing (4)
Drug shortages (1)
Duchenne muscular dystrophy (2)
Earnings (4493)
Editorial (4)
Employer branding (2)
Employer resources (21)
Events (5873)
Executive appointments (68)
FDA (1205)
Frontotemporal dementia (1)
Funding (97)
Gene editing (12)
Generative AI (4)
Gene therapy (20)
GLP-1 (52)
Government (489)
Grass and pollen (1)
Guidances (4)
Healthcare (1550)
Huntington's disease (1)
Immunology and inflammation (7)
Infectious disease (534)
Inflammatory bowel disease (11)
Influenza (16)
Intellectual property (4)
Interviews (34)
IPO (915)
IRA (2)
Job creations (513)
Job search strategy (198)
Labor market (9)
Layoffs (42)
Leadership (9)
Legal (380)
Liver cancer (2)
Lung cancer (18)
Lymphoma (10)
Machine learning (3)
Management (5)
Manufacturing (46)
Medical device (985)
Medtech (985)
Mergers & acquisitions (1815)
Metabolic disorders (26)
Multiple sclerosis (3)
Neurodegenerative disease (3)
Neuropsychiatric disorders (1)
Neuroscience (154)
NextGen: Class of 2025 (716)
Non-profit (549)
Now hiring (12)
Obesity (19)
Opinion (41)
Ovarian cancer (5)
Pain (7)
Pancreatic cancer (5)
Parkinson's disease (14)
Partnered (6)
Patents (7)
Patient recruitment (5)
Peanut (3)
People (4802)
Pharmaceutical (2)
Phase I (708)
Phase II (890)
Phase III (697)
Pipeline (117)
Policy (6)
Postmarket research (98)
Preclinical (505)
Press Release (18)
Prostate cancer (12)
Psychedelics (4)
Radiopharmaceuticals (12)
Rare diseases (14)
Real estate (1431)
Recruiting (13)
Regulatory (1479)
Reports (11)
Research institute (529)
Resumes & cover letters (30)
Rett syndrome (1)
RNA editing (1)
RSV (4)
Schizophrenia (3)
Series A (18)
Series B (8)
Service/supplier (2)
Sickle cell disease (1)
Special edition (2)
Spinal muscular atrophy (5)
Sponsored (6)
Startups (491)
Supply chain (8)
Tariffs (3)
Vaccines (42)
Venture capitalists (5)
Weight loss (10)
Women's health (2)
Worklife (4)
Date
Today (14)
Last 7 days (57)
Last 30 days (216)
Last 365 days (2543)
2025 (821)
2024 (2833)
2023 (3374)
2022 (4910)
2021 (5062)
2020 (5680)
2019 (4238)
2018 (3037)
2017 (2964)
2016 (3167)
2015 (3192)
2014 (2226)
2013 (1958)
2012 (2099)
2011 (2209)
2010 (1633)
Location
Africa (109)
Alabama (6)
Alaska (1)
Arizona (22)
Arkansas (1)
Asia (3100)
Australia (488)
California (451)
Canada (149)
China (32)
Colorado (19)
Connecticut (40)
Delaware (8)
Europe (6164)
Florida (37)
Georgia (21)
Idaho (3)
Illinois (35)
India (6)
Indiana (31)
Iowa (3)
Japan (8)
Kansas (5)
Kentucky (1)
Louisiana (1)
Maine (6)
Maryland (54)
Massachusetts (376)
Michigan (59)
Minnesota (30)
Missouri (13)
Montana (3)
Nebraska (5)
Nevada (6)
New Hampshire (6)
New Jersey (99)
New Mexico (11)
New York (159)
North Carolina (93)
North Dakota (2)
Northern California (205)
Ohio (37)
Oklahoma (3)
Oregon (6)
Pennsylvania (109)
Rhode Island (2)
South America (190)
South Carolina (4)
Southern California (148)
Tennessee (19)
Texas (70)
United States (1873)
Utah (33)
Virginia (14)
Washington D.C. (2)
Washington State (45)
West Virginia (1)
Wisconsin (8)
55,504 Results for "pax labs".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Repligen Appoints Maggie A. Pax to Board of Directors
Repligen Corporation announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax.
March 19, 2024
·
4 min read
Pharm Country
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin.
April 11, 2024
·
5 min read
Business
Alimera Appoints Maggie A. Pax to Its Board of Directors
Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces the addition of Maggie A. Pax to its Board of Directors.
November 8, 2023
·
3 min read
Drug Development
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
August 27, 2024
·
6 min read
Pharm Country
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders.
May 7, 2024
·
4 min read
Biotech Bay
Novel Research by PAX and Zentrela Suggests Cannabis “Entourage Effect,” Not THC Potency, Responsible for Psychoactive Experience
PAX, a leading global cannabis brand, today announced a collaboration with pioneering Canadian neurotechnology company, Zentrela, leveraging brainwave research to provide consumers with data-driven insight into cannabis effects — ultimately supporting more informed purchasing and consumption decisions.
October 3, 2023
·
3 min read
Deals
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
PaxMedica, Inc. today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq.
May 15, 2024
·
5 min read
Drug Development
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
PaxMedica, Inc. today announced positive top line data for the Company’s PAX-HAT-301 Retrospective Analysis of Suramin Treatment for Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (S1 TBR HAT).
July 24, 2023
·
10 min read
Pharm Country
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
PaxMedica Inc., a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health of Malawi, a country in east Africa.
April 23, 2024
·
4 min read
BioMidwest
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
PaxMedica, Inc. (Nasdaq: PXMD) and Vox Nova LLC (VoxNova), a privately held corporation, today announced that they have signed an exclusive pharmacy distribution agreement for PaxMedica’s lead pipeline asset, PAX-101.
July 6, 2023
·
6 min read
1 of 5,551
Next
